07.02.2018 – 18:00

Zur Rose AG

EQS-News: Zur Rose Group AG: Statement on the draft coalition agreement in Germany: Rx mail-order ban not to be justified

EQS Group-News: Zur Rose Group AG / Key word(s): Statement
Zur Rose Group AG: Statement on the draft coalition agreement in Germany: Rx
mail-order ban not to be justified

07.02.2018 / 17:49

--------------------------------------------------------------------------------
Press release

Statement on the draft coalition agreement in Germany: Rx mail-order ban not to
be justified

As per the draft coalition agreement of the parties CDU/CSU and SPD published
today the parties intend to implement a ban on mail-order of prescription drugs
in order to strengthen local pharmacies. Based on expert opinions and statements
of previous federal governments, the Zur Rose Group remains convinced that this
intention is unconstitutional and incompatible with European law. The company is
therefore very surprised that these assessments were apparently not sufficiently
considered and that this intention was included in the draft coalition
agreement. In the interest of patients the Zur Rose Group will therefore take
all necessary legal and operative steps both in Germany and at European level.

Investor and analyst contact
Marcel Ziwica, Chief Financial Officer
e-mail:  ir@zurrose.com, telephone: +41 52 724 00 64

Media contact
Lisa Lüthi, Head of Corporate Communications
e-mail:  lisa.luethi@zurrose.com, telephone: +41 52 724 08 14

Zur Rose Group

Operating under the Zur Rose and DocMorris brands, the Swiss-based Zur Rose
Group is Europe's leading online pharmacy and one of Switzerland's foremost
wholesale suppliers to medical doctors. Through its business model, it helps to
ensure safe, reliable and high-quality pharmaceutical care. while also excelling
in developing innovative medicines management services to increase the
effectiveness of the medication process. This creation of added value, the
strong focus on patients and the commitment to supply medication at low cost for
the benefit of payors and patients make the Group an important strategic partner
for all healthcare stakeholders.

The Zur Rose Group is headquartered in Frauenfeld, from where it also serves the
Swiss market. Customers in Germany and Austria are primarily supplied from
Heerlen (NL). Furthermore, the Group holds a majority interest in BlueCare in
Winterthur, the leading provider of networking systems in the Swiss healthcare
market. Employing more than 1000 people at its various locations, Zur Rose Group
generated revenue of CHF 983 million in 2017. Zur Rose Group AG's shares (ticker
symbol ROSE, Swiss security no. 4261528, ISIN CH0042615283) are traded on SIX
Swiss Exchange. More information at zurrosegroup.com.

--------------------------------------------------------------------------------
End of Corporate News
--------------------------------------------------------------------------------

Language: English

Company:  Zur Rose Group AG

          Walzmühlestrasse 60

          8500 Frauenfeld

          Switzerland

Phone:    +41 52 724 08 14

Internet: www.zurrosegroup.com

ISIN:     CH0199729366, CH0042615283

Listed:   SIX Swiss Exchange



 

End of News EQS Group News Service

--------------------------------------------------------------------------------

652387  07.02.2018